Evolocumab reduces cardiovascular events in patients with heart disease, finds study

Evolocumab reduced the risk of major cardiovascular events by 15% in patients with atherosclerotic cardiovascular disease who were already taking statins, a study has found.

The study randomised 27 564 patients with clinically evident atherosclerotic cardiovascular disease to evolocumab (either 140 mg every two weeks or 420 mg monthly by subcutaneous injection) or to placebo.1 Study participants had fasting concentrations of low density lipoprotein (LDL) cholesterol of ≥1.8 mmol/L on moderate or high intensity statin therapy, and 81% had a …